argenex SE $ARGX Shares Acquired by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd grew its position in shares of argenex SE (NASDAQ:ARGX) by 41.1% in the 1st quarter, Holdings Channel.com reports. The firm owned 5,884 shares of the company’s stock after buying an additional 1,714 shares during the period. Y Intercept Hong Kong Ltd’s holdings in argenex were worth $4,297,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in the company. Abound Wealth Management raised its position in shares of argenex by 3,200.0% in the fourth quarter. Abound Wealth Management now owns 33 shares of the company’s stock worth $28,000 after acquiring an additional 32 shares during the period. Sound Income Strategies LLC purchased a new position in shares of argenex in the 4th quarter valued at about $28,000. Ameriflex Group Inc. purchased a new position in shares of argenex in the 3rd quarter valued at about $32,000. Aventura Private Wealth LLC acquired a new position in argenex in the 4th quarter worth about $38,000. Finally, Sunbelt Securities Inc. acquired a new position in argenex in the 3rd quarter worth about $36,000. 60.32% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have commented on the company. Wedbush reissued an “outperform” rating and issued a $1,000.00 price objective on shares of argenex in a report on Thursday, June 11th. HC Wainwright reiterated a “buy” rating and set a $940.00 target price on shares of argenex in a research report on Thursday, June 25th. Glj Research raised shares of argenex to a “strong-buy” rating in a research note on Friday, April 3rd. Wells Fargo & Company upped their price objective on shares of argenex from $1,260.00 to $1,291.00 and gave the stock an “overweight” rating in a research report on Monday, June 1st. Finally, Wall Street Zen downgraded shares of argenex from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $1,034.56.

argenex Stock Performance

NASDAQ:ARGX opened at $939.68 on Monday. The company’s 50-day moving average price is $840.98 and its 200-day moving average price is $810.88. The company has a market cap of $58.44 billion, a P/E ratio of 41.84, a P/E/G ratio of 1.16 and a beta of 0.45. argenex SE has a twelve month low of $536.02 and a twelve month high of $953.58.

argenex (NASDAQ:ARGX) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $5.52 earnings per share (EPS) for the quarter. argenex had a net margin of 31.31% and a return on equity of 44.37%. The company had revenue of $1.31 billion during the quarter. On average, analysts expect that argenex SE will post 26.27 earnings per share for the current year.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.